

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Naoya KOJIMA et al.

Appl. No. : 10/598,916

I. A. Filed : March 17, 2005



Group Art Unit : 1633

Examiner : Ileana POPA

Confirmation No. : 2020

For : DRUG DELIVERY SYSTEM USING AN IMMUNE RESPONSE SYSTEM

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, and supplemental to the Information Disclosure Statements filed August 15, 2007, and June 27, 2008, Applicants hereby bring the following information to the attention of the Examiner:

- JP 54-113417, published September 5, 1979, along with an English language abstract of corresponding document GB 2 013 087 provided by Esp@cenet;
- GB 2 013 087, published August 8, 1979; Applicants note that this document is a patent family member of JP 54-113417, listed above;
- Ikehara et al. "A Carbohydrate Recognition-Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle" *Cancer Res.* **66**:8740-8748, 2006;
- Altin et al. "Liposomal vaccines – targeting the delivery of antigen" *Methods* **40**:39-52, 2006;
- Mizuochi, T. "Carbohydrate Engineering," Industrial Research Center, Biotechnology Information Center, pages 224-232, 1992;

01/21/2009 SMOHAMME 00000027 10598916

01 FC:1806

180.00 0P

- Fujiwara et al. "Functional Analysis of Peritoneal Lymphoid Tissues by GFP Expression in Mice – Possible Application for Targeting Gene Therapy against Peritoneal Dissemination" *Jpn. J. Cancer Chemother.* 29(12):2322-2324, 2002, along with an English language summary of the same; and
- Shimoma et al. "Role of omental milky spots in peritoneal metastases of carcinoma" *Oncologia* 24(3):80-85, 1991, along with an English language summary of the same.

With regard to the Fujiwara et al. and Shimoma et al. documents, listed above, Applicants particularly direct the Examiner's attention to the English language summary set forth in each document. With regard to the Mizuochi document listed above, Applicants submit that this document is cited and discussed in the present specification beginning at page 9, line 18. Specifically, page 9 of the instant specification cites this document in the following context:

Any of the oligosaccharides described above contains one reducing terminal aldehyde group. Thus this aldehyde group can be utilized as a means for introducing the oligosaccharide to the surface of a liposome. That is, a Schiff base is formed by reacting this aldehyde with a lipid containing amino groups, and then the oligosaccharide and the lipid can be linked by reducing the Schiff base with a standard method, preferably by chemical reduction, for example, by NaBH<sub>3</sub>CN (Mizuochi, Tsuguo, Carbohydrate Engineering, pp 224-232, Industrial Research Center, Biotechnology Information Center, 1992).

Moreover, copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. Therefore, Applicants respectfully submit that the instant Information Disclosure Statement is compliant with 37 C.F.R. §§ 1.97 - 1.98, and in particular, with 37 C.F.R. § 1.98(c)(i), and respectfully request the Examiner to consider the same. The Examiner is further requested to make the information therein of record in the instant application by initialing in the appropriate spaces on the Form PTO-1449 and including a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that this second Supplemental Information Disclosure Statement is being filed after a non-final Office Action on the merits. Accordingly, as set forth in 37 C.F.R. § 1.17(p), Applicants enclose herewith the fee for consideration of this second Supplemental Information Disclosure Statement. However, if any other fee is deemed necessary to ensure the consideration of the submitted documents, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089.

Should there be any questions, the Examiner is invited to contact the undersigned at the below listed telephone number.

Respectfully Submitted,  
Naoya KOJIMA et al.

  
Bruce H. Bernstein  
Reg. No. 29,027  
*42,920*

January 15, 2009  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191